X4 Pharmaceuticals, Inc. Common Stock (XFOR) — Analysis Summary
X4 Pharmaceuticals, Inc. Common Stock (XFOR) has a market cap of $381.99M with year-over-year revenue growth of +1273.2%. Net margin stands at -225.6%. The stock trades at a P/E ratio of -3.8.
Key Takeaways
- Revenue changed +1273.2% year-over-year
- Net margin of -225.6%
- P/E ratio of -3.8
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, XFOR posted revenue growth of +1273.2% and trades at a P/E of -3.8.
X4 Pharmaceuticals, Inc. Common Stock (XFOR)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -11.1x — earnings do not cover interest payments
Operating margin at -1084.4% — severe operating losses
Net margin at -1106.3% — losses exceed revenue (possible one-time charges)
Revenue fell 74.3% vs the prior period.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
45
Headquarters
BOSTON, MA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.